MARTIN SHKRELI

Shkreli, a former pharmaceutical executive known for raising the price of a life-saving drug by 5,000%, was sentenced to seven years in prison in for securities fraud in 2018.

Convicted pharmaceutical executive Martin Shkreli has been freed from prison after serving much of a seven-year prison sentence for lying to hedge fund investors and cheating investors in a drug company.

Martin Shkreli will his securities fraud sentence in September. He gained infamy for raising the price of a drug by more than 4,000%.

Shkreli has been released from an Allenwood, Pa. prison early and is being taken by a friend to a halfway house, according to a statement from his lawyer.

Martin Shkreli lost the civil case involving the drug Daraprim while serving a criminal sentence for unrelated securities fraud.

Questions about Donald Trump’s business practices are piling up.

Martin Shkreli raised the price of the prescription drug Daraprim by more than 4,000. He recently was banned for life from the pharmaceutical industry.

The so-called "Pharma Bro" was sued in early 2020 for an alleged antitrust violation over the price of the drug Daraprim.

Martin Shkreli, who is serving a seven-year prison sentence for fraud, must return profits he and his former company reaped from raising the price of a life-saving drug, a federal judge ruled.

"Pharma Bro" Martin Shkreli was banned for life from the pharmaceutical industry and ordered to pay $64.6 million in profits from the drug Daraprim.

A federal judge has ordered Martin Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life.

A company once owned by “Pharma Bro” Martin Shkreli will pay up to $40 million to settle allegations that it jacked up the price of a life-saving medication by roughly 4 ,000% after obtaining exclusive rights to the drug.

Proceeds for the sale will go towards Shkreli's court-ordered fines and payments.

A Wu-Tang Clan album once owned by felon Martin Shkreli was sold by the U.S. government to satisfy as much as a $2.3 million forfeiture balance.

The entrepreneur known as “Pharma Bro” once boasted that he paid $2 million in 2015 at auction for “Once Upon a Time in Shaolin,” the 31-track double album the Wu-Tang Clan spent six years creating. Authorities said the sales contract for the album contained a confidentiality provision that protects information relating to the buyer and price. In a civil case in Manhattan federal court, lawyers wrote in an April document that Shkreli had already reduced his forfeiture debt by about $5 million. Shkreli’s purchase of the Wu-Tang Clan album came as group member RZA said he wanted the album — packaged in a hand-crafted silver and nickel case which includes a 174-page book wrapped in leather — to be viewed as a piece of contemporary art. Brafman described Shkreli at sentencing as a misunderstood eccentric who used unconventional means to make his defrauded investors even wealthier.

An unreleased Wu-Tang Clan album forfeited by Martin Shkreli after his fraud conviction has been sold.

The proceeds for the sale will go towards Shkreli's court-ordered fines and payments.

There was only one copy of Once Upon a Time in Shaolin, and the government forced Shkreli to turn it over after his fraud conviction. Details are confidential, so don't expect to hear it anytime soon.

A unique Wu-Tang Clan album has been sold by the U.S. government, after Pharma Bro Martin Shkreli forfeited it as part of his 2017 federal criminal conviction.

The News Leaders Association has given Ron Nixon of The Associated Press its first-ever News Leader of the Year award.

Matsumoto noted that Shkreli recently had a two-hour Zoom session with his lawyers, as well as several phone calls up to an hour in length. Prosecutors said that, as of January 6, there were no positive cases in Shkreli's housing unit. In her ruling, Matsumoto wrote that Shkreli is a "relatively young and healthy man" and won't be at high risk of severe complications if he were to contract the disease. Shkreli, who was ordered to forfeit $7.3 million as part of his sentence, is due to be released from prison in September 2023. In his original request for compassionate release, Shkreli asked to be let out of prison for three months to put his background "as a successful two-time biopharma entrepreneur" to work researching a coronavirus treatment "under strict supervision."

FILE - In this Aug. 3, 2017, file photo, Martin Shkreli arrives at federal court in New York. Matsumoto noted that Shkreli recently had a two-hour Zoom session with his lawyers, as well as several phone calls up to an hour in length. Prosecutors said that, as of Jan. 6, there were no positive cases in Shkreli’s housing unit. Shkreli, who was ordered to forfeit $7.3 million as part of his sentence, is due to be released from prison in September 2023. He is also known for attacking critics on social media and offering a bounty to anyone who could give him one of Hillary Clinton’s hairs.

But for me, it's just the latest crappy e-commerce ad, which are all over the internet these days. But none of these have captured the eye of so many quite like the butt-flap pajamas. There are several ways this particular ad simultaneously could have found its way onto the screens of many. As for the actual design of the ad, Vidakovic says it's likely very intentional as well. "It means that brand, whoever is paying for these ads, they're probably paying a not insignificant amount," he said.

NEW YORK A judge rejected the request of convicted pharmaceutical executive Martin Shkreli to be let out of prison to research a coronavirus treatment, noting that probation officials viewed that claim as the type of delusional self-aggrandizing behavior that led to his conviction. U.S. District Judge Kiyo Matsumoto said in a nine-page ruling Saturday that the man known as the Pharma Bro" failed to demonstrate extraordinary and compelling factors that would require his release under home confinement rules designed to move vulnerable inmates out of institutions during the pandemic. Disappointed but not unexpected, Shkrelis lawyer, Benjamin Brafman, said. A judge ordered Shkreli to forfeit $7.3 million. He is also known for attacking critics on social media and offering a bounty to anyone who could give him one of Hillary Clintons hairs.

Federal prosecutors on Wednesday called notorious pharmaceutical industry fraudster Martin Shkreli "delusional" and greedy as they opposed his bid to win early release from prison to both avoid catching the coronavirus and to work on a potential cure for it. Shkreli's lawyer, Benjamin Brafman, when asked for comment about the prosecutors' new filing, wrote in an email, 'Was hoping for a more compassionate response." Their filing said Shkreli's own request last week belies the need to release him so that he can continue his research into a coronavirus treatment. "There is no evidence that Shkreli has changed in this, or any other, respect," prosecutors wrote. "Shkreli continues to believe that the rules do not apply to him," prosecutors wrote.

Ex-pharmaceutical executive Martin Shkreli arrives at the U.S. District Court for the Eastern District of New York in June, 2017. The Federal Trade Commission and New York's attorney general on Monday sued incarcerated "pharma bro" Martin Shkreli and his firm Vyera Pharmaceuticals for allegedly "illegally monopolizing" the anti-parasite medication Daraprim costing patients and other purchasers to pay tens of millions of dollars more each year than they otherwise would. "Daraprim is a lifesaving drug for vulnerable patients," said Gail Levine, Deputy Director of the Bureau of Competition at the Federal Trade Commission. "Vyera kept the price of Daraprim astronomically high by illegally boxing out the competition." And the suit the suit seeks to enjoin Vyera's conduct, and obtain monetary relief from the alleged victims of the company's conduct.

In a video live chat Thursday, Martin Shkreli took questions from the general public following a congressional hearing in Washington, D.C. where he stonewalled Congress. And Congress wasn't the only one Shkreli stonewalled. When CBS News' Valdimir Duthiers joined the online video chat, Shkreli immediately shut him down. CBSN has more.

Pharmaceutical CEO Martin Shkreli who was accused of price gouging is out on bail after his arrest Thursday on unrelated securities fraud charges. Federal prosecutors allege Shkreli lied and stole to keep his other companies afloat. He was already called a symbol of corporate greed after his drug company raised the price of a medicine by more than 5,000 percent. Anthony Mason reports.

Price-gouging pharma CEO Martin Shkreli arrested on securities fraud charges, San Bernardino shooter's friend charged with terrorism-related counts, and more of the stories you're clicking on.

Martin Shkreli, the notorious pharmaceutical CEO who raised the price of a life-saving drug was arrested on charges of securities fraud. St. John's University School of Law Professor Michael Perino discussed the charges with CBSN's Contessa Brewer.

Martin Shkreli, the pharmaceutical company CEO who caused a public uproar after drastically raising the price of a life-saving prescription drug, was arrested on Thursday; Some superfans bring their devotion to Star Wars into their every-day lives.

Martin Shkreli, who ignited a firestorm when he hiked the price of a life-saving drug from $13.50 up to $750, was arrested Thursday on an unrelated matter. CBS News' DeMarco Morgan and Attorney Matthew Kaiser explain the federal case against him for securities fraud.

Controversial Turing Pharmaceuticals CEO Martin Shkreli has been arrested on charges of securities fraud. CBS News correspondent DeMarco Morgan has the latest for CBSN.

Turing Pharmaceuticals CEO Martin Shkreli is the focus of even more scrutiny following his arrest for securities fraud. CBS News correspondent Vinita Nair joins CBSN with details.

There is more controversy over prescription drug prices and Turing Pharmaceuticals CEO Martin Shkreli. Shkreli caused a public uproar when he drastically raised the price of a lifesaving drug for cancer and AIDS patients. He promised to cut the cost, but that was two months ago. Now he's saying he will reduce the price for hospitals only, not individuals. Don Dahler reports.

When Turing Pharmaceuticals bought a 62-year-old drug called Daraprim in August, the company immediately raised the price of one pill from $13.50 to $750. The increase drew protests in the medical community from those concerned that many patients will no longer be able to afford the drug. Don Dahler spoke to Turing CEO Martin Shkreli, who says the move is simply a smart business decision.